Enliven Therapeutics announces positive Phase 1 trial results for ELVN-001 in CML-resistant patients, showing a 44% initial cumulative major molecular response rate with minimal side effects.
Enliven Therapeutics announces positive proof of concept data from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia (CML) patients resistant to existing tyrosine kinase inhibitors (TKIs). ELVN-001 showed a 44% initial cumulative major molecular response rate by 12 weeks, with no severe non-hematologic side effects. The company plans a virtual event with key opinion leaders.
April 11, 2024
3 Articles